Nature, Published online: 26 June 2026; doi:10.1038/d41586-026-01976-w
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder.CRISPR’s next act: the companies editing the epigenome to treat disease
Nature, Published online: 26 June 2026; doi:10.1038/d41586-026-01976-wA handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder.